ID   NMNA2_HUMAN             Reviewed;         307 AA.
AC   Q9BZQ4; O75067; Q5T1Q3; Q8WU99; Q96QW1;
DT   09-MAY-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   12-APR-2017, entry version 130.
DE   RecName: Full=Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 2 {ECO:0000305};
DE            Short=NMN/NaMN adenylyltransferase 2;
DE            EC=2.7.7.1;
DE            EC=2.7.7.18;
DE   AltName: Full=Nicotinamide mononucleotide adenylyltransferase 2;
DE            Short=NMN adenylyltransferase 2;
DE   AltName: Full=Nicotinate-nucleotide adenylyltransferase 2;
DE            Short=NaMN adenylyltransferase 2;
GN   Name=NMNAT2; Synonyms=C1orf15, KIAA0479;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11318611; DOI=10.1006/geno.2001.6500;
RA   Sood R., Bonner T.I., Malakowska I., Stephan D.A., Robbins C.M.,
RA   Connors T.D., Morgenbesser S.D., Su K., Faruque M.U., Pinkett H.,
RA   Graham C., Baxevanis A.D., Klinger K.W., Landes G.M., Trent J.M.,
RA   Carpten J.D.;
RT   "Cloning and characterization of 13 novel transcripts and the human
RT   RGS8 gene from the 1q25 region encompassing the hereditary prostate
RT   cancer (HPC1) locus.";
RL   Genomics 73:211-222(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9455484; DOI=10.1093/dnares/4.5.345;
RA   Seki N., Ohira M., Nagase T., Ishikawa K., Miyajima N., Nakajima D.,
RA   Nomura N., Ohara O.;
RT   "Characterization of cDNA clones in size-fractionated cDNA libraries
RT   from human brain.";
RL   DNA Res. 4:345-349(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Lung carcinoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   SUBUNIT, COFACTOR, TISSUE SPECIFICITY, AND PH DEPENDENCE.
RX   PubMed=12359228; DOI=10.1016/S0006-291X(02)02285-4;
RA   Raffaelli N., Sorci L., Amici A., Emanuelli M., Mazzola F., Magni G.;
RT   "Identification of a novel human nicotinamide mononucleotide
RT   adenylyltransferase.";
RL   Biochem. Biophys. Res. Commun. 297:835-840(2002).
RN   [6]
RP   MUTAGENESIS OF HIS-24 AND TRP-92, COFACTOR, AND TISSUE SPECIFICITY.
RX   PubMed=14516279; DOI=10.1042/BJ20030518;
RA   Yalowitz J.A., Xiao S., Biju M.P., Antony A.C., Cummings O.W.,
RA   Deeg M.A., Jayaram H.N.;
RT   "Characterization of human brain nicotinamide 5'-mononucleotide
RT   adenylyltransferase-2 and expression in human pancreas.";
RL   Biochem. J. 377:317-326(2004).
RN   [7]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, SUBSTRATE SPECIFICITY,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16118205; DOI=10.1074/jbc.M508660200;
RA   Berger F., Lau C., Dahlmann M., Ziegler M.;
RT   "Subcellular compartmentation and differential catalytic properties of
RT   the three human nicotinamide mononucleotide adenylyltransferase
RT   isoforms.";
RL   J. Biol. Chem. 280:36334-36341(2005).
RN   [8]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, ENZYME REGULATION, AND
RP   COFACTOR.
RX   PubMed=17402747; DOI=10.1021/bi6023379;
RA   Sorci L., Cimadamore F., Scotti S., Petrelli R., Cappellacci L.,
RA   Franchetti P., Orsomando G., Magni G.;
RT   "Initial-rate kinetics of human NMN-adenylyltransferases: substrate
RT   and metal ion specificity, inhibition by products and multisubstrate
RT   analogues, and isozyme contributions to NAD+ biosynthesis.";
RL   Biochemistry 46:4912-4922(2007).
CC   -!- FUNCTION: Catalyzes the formation of NAD(+) from nicotinamide
CC       mononucleotide (NMN) and ATP. Can also use the deamidated form;
CC       nicotinic acid mononucleotide (NaMN) as substrate but with a lower
CC       efficiency. Cannot use triazofurin monophosphate (TrMP) as
CC       substrate. Also catalyzes the reverse reaction, i.e. the
CC       pyrophosphorolytic cleavage of NAD(+). For the pyrophosphorolytic
CC       activity prefers NAD(+), NADH and NaAD as substrates and degrades
CC       nicotinic acid adenine dinucleotide phosphate (NHD) less
CC       effectively. Fails to cleave phosphorylated dinucleotides NADP(+),
CC       NADPH and NaADP(+). {ECO:0000269|PubMed:16118205,
CC       ECO:0000269|PubMed:17402747}.
CC   -!- CATALYTIC ACTIVITY: ATP + nicotinamide ribonucleotide =
CC       diphosphate + NAD(+).
CC   -!- CATALYTIC ACTIVITY: ATP + beta-nicotinate-D-ribonucleotide =
CC       diphosphate + deamido-NAD(+).
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:12359228,
CC         ECO:0000269|PubMed:14516279, ECO:0000269|PubMed:17402747};
CC       Note=Divalent metal cations. Mg(2+) confers the highest activity.
CC       {ECO:0000269|PubMed:12359228, ECO:0000269|PubMed:14516279,
CC       ECO:0000269|PubMed:17402747};
CC   -!- ENZYME REGULATION: Inhibited by P1-(adenosine-5')-P3-
CC       (nicotinamide-riboside-5')-triphosphate (Np3AD) and P1-(adenosine-
CC       5')-P4-(nicotinamide-riboside-5')-tetraphosphate (Np4AD).
CC       {ECO:0000269|PubMed:17402747}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=32 uM for NMN {ECO:0000269|PubMed:16118205,
CC         ECO:0000269|PubMed:17402747};
CC         KM=70 uM for NAD(+) {ECO:0000269|PubMed:16118205,
CC         ECO:0000269|PubMed:17402747};
CC         KM=204 uM for ATP {ECO:0000269|PubMed:16118205,
CC         ECO:0000269|PubMed:17402747};
CC         KM=1119 uM for PPi {ECO:0000269|PubMed:16118205,
CC         ECO:0000269|PubMed:17402747};
CC         KM=14.5 uM for NaMN {ECO:0000269|PubMed:16118205,
CC         ECO:0000269|PubMed:17402747};
CC         KM=304 uM for NMNH {ECO:0000269|PubMed:16118205,
CC         ECO:0000269|PubMed:17402747};
CC         Vmax=1.1 umol/min/mg enzyme for NAD synthesis
CC         {ECO:0000269|PubMed:16118205, ECO:0000269|PubMed:17402747};
CC         Vmax=3 umol/min/mg enzyme for pyrophosphorolytic NAD(+) cleavage
CC         {ECO:0000269|PubMed:16118205, ECO:0000269|PubMed:17402747};
CC         Vmax=7 umol/min/mg enzyme for pyrophosphorolytic NADH cleavage
CC         {ECO:0000269|PubMed:16118205, ECO:0000269|PubMed:17402747};
CC         Note=KM is >100 uM for triazofurin monophosphate.;
CC       pH dependence:
CC         Optimum pH is 6.0-9.0. {ECO:0000269|PubMed:12359228,
CC         ECO:0000269|PubMed:16118205, ECO:0000269|PubMed:17402747};
CC   -!- PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; NAD(+) from
CC       nicotinamide D-ribonucleotide: step 1/1.
CC   -!- PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; deamido-
CC       NAD(+) from nicotinate D-ribonucleotide: step 1/1.
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:12359228}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16118205}.
CC       Golgi apparatus {ECO:0000269|PubMed:16118205}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9BZQ4-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BZQ4-2; Sequence=VSP_015571;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain, in particular in
CC       cerebrum, cerebellum, occipital lobe, frontal lobe, temporal lobe
CC       and putamen. Also found in the heart, skeletal muscle, pancreas
CC       and islets of Langerhans. {ECO:0000269|PubMed:12359228,
CC       ECO:0000269|PubMed:14516279, ECO:0000269|PubMed:16118205}.
CC   -!- SIMILARITY: Belongs to the eukaryotic NMN adenylyltransferase
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA32324.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF288395; AAG60615.1; -; mRNA.
DR   EMBL; AB007948; BAA32324.1; ALT_INIT; mRNA.
DR   EMBL; AL354953; CAH70979.1; -; Genomic_DNA.
DR   EMBL; AL356981; CAH70979.1; JOINED; Genomic_DNA.
DR   EMBL; AL354953; CAH70982.1; -; Genomic_DNA.
DR   EMBL; AL356981; CAH70982.1; JOINED; Genomic_DNA.
DR   EMBL; AL449223; CAH70982.1; JOINED; Genomic_DNA.
DR   EMBL; AL356981; CAI15467.1; -; Genomic_DNA.
DR   EMBL; AL354953; CAI15467.1; JOINED; Genomic_DNA.
DR   EMBL; AL356981; CAI15468.1; -; Genomic_DNA.
DR   EMBL; AL354953; CAI15468.1; JOINED; Genomic_DNA.
DR   EMBL; AL449223; CAI15468.1; JOINED; Genomic_DNA.
DR   EMBL; AL449223; CAI16624.1; -; Genomic_DNA.
DR   EMBL; AL354953; CAI16624.1; JOINED; Genomic_DNA.
DR   EMBL; AL356981; CAI16624.1; JOINED; Genomic_DNA.
DR   EMBL; BC020998; AAH20998.1; -; mRNA.
DR   CCDS; CCDS1353.1; -. [Q9BZQ4-1]
DR   CCDS; CCDS1354.1; -. [Q9BZQ4-2]
DR   RefSeq; NP_055854.1; NM_015039.3. [Q9BZQ4-1]
DR   RefSeq; NP_733820.1; NM_170706.3. [Q9BZQ4-2]
DR   UniGene; Hs.497123; -.
DR   ProteinModelPortal; Q9BZQ4; -.
DR   BioGrid; 116693; 1.
DR   DIP; DIP-60169N; -.
DR   STRING; 9606.ENSP00000287713; -.
DR   iPTMnet; Q9BZQ4; -.
DR   PhosphoSitePlus; Q9BZQ4; -.
DR   BioMuta; NMNAT2; -.
DR   DMDM; 30580486; -.
DR   PaxDb; Q9BZQ4; -.
DR   PeptideAtlas; Q9BZQ4; -.
DR   PRIDE; Q9BZQ4; -.
DR   DNASU; 23057; -.
DR   Ensembl; ENST00000287713; ENSP00000287713; ENSG00000157064. [Q9BZQ4-1]
DR   Ensembl; ENST00000294868; ENSP00000294868; ENSG00000157064. [Q9BZQ4-2]
DR   GeneID; 23057; -.
DR   KEGG; hsa:23057; -.
DR   UCSC; uc001gqb.2; human. [Q9BZQ4-1]
DR   CTD; 23057; -.
DR   DisGeNET; 23057; -.
DR   GeneCards; NMNAT2; -.
DR   HGNC; HGNC:16789; NMNAT2.
DR   MIM; 608701; gene.
DR   neXtProt; NX_Q9BZQ4; -.
DR   OpenTargets; ENSG00000157064; -.
DR   PharmGKB; PA25604; -.
DR   eggNOG; KOG3199; Eukaryota.
DR   eggNOG; COG1057; LUCA.
DR   GeneTree; ENSGT00530000063189; -.
DR   HOGENOM; HOG000216047; -.
DR   HOVERGEN; HBG052640; -.
DR   InParanoid; Q9BZQ4; -.
DR   KO; K06210; -.
DR   OMA; YILQSQL; -.
DR   OrthoDB; EOG091G0JTI; -.
DR   PhylomeDB; Q9BZQ4; -.
DR   TreeFam; TF315035; -.
DR   BioCyc; MetaCyc:HS08173-MONOMER; -.
DR   BRENDA; 2.7.7.1; 2681.
DR   BRENDA; 2.7.7.18; 2681.
DR   Reactome; R-HSA-196807; Nicotinate metabolism.
DR   SABIO-RK; Q9BZQ4; -.
DR   UniPathway; UPA00253; UER00332.
DR   UniPathway; UPA00253; UER00600.
DR   ChiTaRS; NMNAT2; human.
DR   GeneWiki; NMNAT2; -.
DR   GenomeRNAi; 23057; -.
DR   PRO; PR:Q9BZQ4; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000157064; -.
DR   CleanEx; HS_NMNAT2; -.
DR   Genevisible; Q9BZQ4; HS.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0005770; C:late endosome; IEA:Ensembl.
DR   GO; GO:0045202; C:synapse; IEA:Ensembl.
DR   GO; GO:0005802; C:trans-Golgi network; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0000309; F:nicotinamide-nucleotide adenylyltransferase activity; IBA:GO_Central.
DR   GO; GO:0004515; F:nicotinate-nucleotide adenylyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0034628; P:'de novo' NAD biosynthetic process from aspartate; IBA:GO_Central.
DR   GO; GO:0009435; P:NAD biosynthetic process; IC:UniProtKB.
DR   GO; GO:0019674; P:NAD metabolic process; TAS:Reactome.
DR   Gene3D; 3.40.50.620; -; 1.
DR   InterPro; IPR004821; Cyt_trans-like.
DR   InterPro; IPR014729; Rossmann-like_a/b/a_fold.
DR   Pfam; PF01467; CTP_transf_like; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Complete proteome; Cytoplasm;
KW   Golgi apparatus; Magnesium; NAD; Nucleotide-binding;
KW   Nucleotidyltransferase; Pyridine nucleotide biosynthesis;
KW   Reference proteome; Transferase.
FT   CHAIN         1    307       Nicotinamide/nicotinic acid
FT                                mononucleotide adenylyltransferase 2.
FT                                /FTId=PRO_0000135014.
FT   NP_BIND      15     17       ATP. {ECO:0000250|UniProtKB:Q96T66}.
FT   NP_BIND     200    202       ATP. {ECO:0000250|UniProtKB:Q96T66}.
FT   NP_BIND     271    274       ATP. {ECO:0000250|UniProtKB:Q96T66}.
FT   REGION       55     57       Substrate binding.
FT                                {ECO:0000250|UniProtKB:Q96T66}.
FT   REGION       92     95       Substrate binding.
FT                                {ECO:0000250|UniProtKB:Q96T66}.
FT   REGION      212    213       Substrate binding.
FT                                {ECO:0000250|UniProtKB:Q96T66}.
FT   BINDING      24     24       ATP. {ECO:0000250|UniProtKB:Q96T66}.
FT   VAR_SEQ       1     28       MTETTKTHVILLACGSFNPITKGHIQMF -> MEIQELEEI
FT                                QACQGLWEVFVTLS (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_015571.
FT   MUTAGEN      24     24       H->A: Reduces activity by 95%.
FT                                {ECO:0000269|PubMed:14516279}.
FT   MUTAGEN      92     92       W->G: Reduces activity by 95%.
FT                                {ECO:0000269|PubMed:14516279}.
SQ   SEQUENCE   307 AA;  34439 MW;  702F1C74B38ECECB CRC64;
     MTETTKTHVI LLACGSFNPI TKGHIQMFER ARDYLHKTGR FIVIGGIVSP VHDSYGKQGL
     VSSRHRLIMC QLAVQNSDWI RVDPWECYQD TWQTTCSVLE HHRDLMKRVT GCILSNVNTP
     SMTPVIGQPQ NETPQPIYQN SNVATKPTAA KILGKVGESL SRICCVRPPV ERFTFVDENA
     NLGTVMRYEE IELRILLLCG SDLLESFCIP GLWNEADMEV IVGDFGIVVV PRDAADTDRI
     MNHSSILRKY KNNIMVVKDD INHPMSVVSS TKSRLALQHG DGHVVDYLSQ PVIDYILKSQ
     LYINASG
//
